Literature DB >> 16389656

Estimation of time-dependent rate ratios in case-control studies: comparison of two approaches for exposure assessment.

Geneviève Lefebvre1, Jean-François Angers, Lucie Blais.   

Abstract

PURPOSE: In pharmacoepidemiology, it is well recognized that the rate of adverse events may vary as a function of the cumulative duration of the drug exposure and/or the time since the end of the exposure. In case-control studies, two different approaches have been used to estimate temporal effects of drug exposure: the time-windows (T-Ws) approach and the duration-specific (D-S) approach. We decided to conduct a simulation study to compare the two approaches when the rate ratios (RRs) vary as a function of the cumulative duration of exposure and/or the time since the end of exposure.
METHODS: We generated three cohorts of 500,000 individuals in which the rate of the event was varying as a function of the cumulative duration of exposure and the time since the end of exposure. For each cohort, a nested case-control analysis was performed using both the D-S and the T-Ws approaches. In the T-Ws approach, a RR is estimated within specific periods of time prior to the outcome, while a RR is estimated within periods of cumulative duration of exposure and time since the end of exposure in the D-S approach.
RESULTS: We found that the RRs obtained from the D-S approach exactly corresponded to the RRs obtained from the cohort analyses, while the RRs obtained from the T-Ws approach generally not. RRs obtained from the T-Ws approach were difficult to interpret in terms of the effect of the duration and timing of the exposure.
CONCLUSION: The D-S approach should be used to investigate the duration-related effects of exposure in case-control studies.

Entities:  

Mesh:

Year:  2006        PMID: 16389656     DOI: 10.1002/pds.1201

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  3 in total

1.  Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.

Authors:  M Pazianas; B Abrahamsen; Y Wang; R G G Russell
Journal:  Osteoporos Int       Date:  2012-03-20       Impact factor: 4.507

2.  Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort.

Authors:  Shou-Chien Hsu; Shy-Shin Chang; Meng-Tse Gabriel Lee; Si-Huei Lee; Yi-Wen Tsai; Shen-Che Lin; Szu-Ta Chen; Yi-Chieh Weng; Lorenzo Porta; Jiunn-Yih Wu; Chien-Chang Lee
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

3.  Identification of causal effects in case-control studies.

Authors:  Bas B L Penning de Vries; Rolf H H Groenwold
Journal:  BMC Med Res Methodol       Date:  2022-01-07       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.